SeqOnce Biosciences

Executive Summary

SeqOnce Biosciences, now operating as Bandit Bio, is a San Diego-based life science tools company specializing in rapid qPCR assays and NGS library preparation kits. Founded in 2019, the company focuses on creating high-performance molecular biology reagents that are compatible with open-source laboratory instruments, aiming to accelerate research workflows and reduce costs. Their products emphasize speed, simplicity, and broad compatibility, positioning them as practical solutions for genomics research. Bandit Bio targets academic, government, and commercial labs seeking efficient, cost-effective alternatives to proprietary systems, thereby unlocking hidden potential in existing research platforms. Despite operating in a competitive landscape dominated by established players like Thermo Fisher and Illumina, Bandit Bio differentiates itself through open-platform compatibility and a focus on accessibility. The company has not disclosed funding rounds or revenue, and its small size suggests an early-stage profile. With the growing demand for affordable and flexible genomics tools, Bandit Bio is well-positioned to capture niche market share. However, the company faces challenges in scaling production and gaining regulatory clearances. Its success will depend on product adoption, partnerships, and securing additional capital to expand commercialization efforts.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation qPCR Kit with Enhanced Sensitivity70% success
• Q4 2026Strategic Partnership with Major Distributor for Global Reach50% success
• Q1 2027Series A Financing Round to Scale Manufacturing60% success